COVID-19 in chronic kidney disease: a retrospective, propensity score-matched cohort study.


Journal

International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 07 07 2020
accepted: 19 01 2021
pubmed: 7 2 2021
medline: 30 9 2021
entrez: 6 2 2021
Statut: ppublish

Résumé

The prognostic factors for COVID-19 in patients with chronic kidney disease (CKD) are uncertain. We conducted a study to compare clinical and prognostic features between hospitalized COVID-19 patients with and without CKD. Fifty-six patients with stage 3-5 CKD and propensity score-matched fifty-six patients without CKD were included in the study. Patients were followed-up at least fifteen days or until death after COVID-19 diagnosis. The endpoints were death from all causes, development of acute kidney injury (AKI) or cytokine release syndrome or respiratory failure, or admission to the intensive care unit (ICU). All patients were reviewed retrospectively over a median follow-up of 44 days (IQR, 36-52) after diagnosis of COVID-19. Patients with CKD had higher intensive care unit admission and mortality rates than the patients without CKD, but these results did not reach statistical significance (16 vs. 19; p = 0.54 and 11 vs. 16, p = 0.269, respectively). The frequency of AKI development was significantly higher in predialysis patients with CKD compared to the other group (8 vs. 5; p < 0.001), but there was no significant difference between the groups in terms of cytokine release syndrome (13 vs. 8; p = 0.226), follow-up in the ICU (19 vs. 16; p = 0.541), and respiratory failure (25 vs. 22, p = 0.566). Multivariate logistic regression analysis revealed that respiratory failure and AKI were independent risk factors for mortality. The mortality rates of COVID-19 patients with CKD had higher than COVID-19 patients without CKD. Also, AKI and respiratory failure were independently related to mortality.

Sections du résumé

BACKGROUND BACKGROUND
The prognostic factors for COVID-19 in patients with chronic kidney disease (CKD) are uncertain. We conducted a study to compare clinical and prognostic features between hospitalized COVID-19 patients with and without CKD.
METHODS METHODS
Fifty-six patients with stage 3-5 CKD and propensity score-matched fifty-six patients without CKD were included in the study. Patients were followed-up at least fifteen days or until death after COVID-19 diagnosis. The endpoints were death from all causes, development of acute kidney injury (AKI) or cytokine release syndrome or respiratory failure, or admission to the intensive care unit (ICU).
RESULTS RESULTS
All patients were reviewed retrospectively over a median follow-up of 44 days (IQR, 36-52) after diagnosis of COVID-19. Patients with CKD had higher intensive care unit admission and mortality rates than the patients without CKD, but these results did not reach statistical significance (16 vs. 19; p = 0.54 and 11 vs. 16, p = 0.269, respectively). The frequency of AKI development was significantly higher in predialysis patients with CKD compared to the other group (8 vs. 5; p < 0.001), but there was no significant difference between the groups in terms of cytokine release syndrome (13 vs. 8; p = 0.226), follow-up in the ICU (19 vs. 16; p = 0.541), and respiratory failure (25 vs. 22, p = 0.566). Multivariate logistic regression analysis revealed that respiratory failure and AKI were independent risk factors for mortality.
CONCLUSION CONCLUSIONS
The mortality rates of COVID-19 patients with CKD had higher than COVID-19 patients without CKD. Also, AKI and respiratory failure were independently related to mortality.

Identifiants

pubmed: 33548044
doi: 10.1007/s11255-021-02783-0
pii: 10.1007/s11255-021-02783-0
pmc: PMC7864795
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2117-2125

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature B.V. part of Springer Nature.

Références

CEN Case Rep. 2021 Feb;10(1):126-131
pubmed: 32940880
Kidney Int. 2005 Jun;67(6):2089-100
pubmed: 15882252
Kidney Int Rep. 2020 May 04;5(6):759-761
pubmed: 32368701
Med J Armed Forces India. 2020 Oct;76(4):370-376
pubmed: 32895599
J Am Soc Nephrol. 2020 Sep;31(9):1969-1975
pubmed: 32732391
J Am Soc Nephrol. 2020 Jul;31(7):1380-1383
pubmed: 32366514
J Am Soc Nephrol. 2020 Jul;31(7):1387-1397
pubmed: 32385130
Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1139-1145
pubmed: 32444393
Kidney Int Rep. 2020 Apr 04;5(5):580-585
pubmed: 32292866
Kidney Int. 2020 Jul;98(1):27-34
pubmed: 32437770
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Am J Kidney Dis. 2021 Jan;77(1):153-154
pubmed: 33011311
Kidney Int Rep. 2020 May 01;5(6):905-909
pubmed: 32363253
Kidney Int. 2020 Dec;98(6):1530-1539
pubmed: 32810523
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Am Soc Nephrol. 2004 Jul;15(7):1883-8
pubmed: 15213277
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Kidney Int. 2020 Dec;98(6):1540-1548
pubmed: 32979369
Lancet Respir Med. 2020 Jul;8(7):738-742
pubmed: 32416769
Int Urol Nephrol. 2020 Jun;52(6):1193-1194
pubmed: 32222883
Int J Infect Dis. 2020 Jun;95:304-307
pubmed: 32344011
Am J Kidney Dis. 2020 Jul;76(1):141-143
pubmed: 32240718

Auteurs

Ahmet Burak Dirim (AB)

Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. ahmetburakdirim@gmail.com.

Erol Demir (E)

Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Serap Yadigar (S)

Division of Nephrology, Department of Internal Medicine, Dr. Lutfi Kirdar Kartal Teaching and Research Hospital, Istanbul, Turkey.

Nurana Garayeva (N)

Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Ergun Parmaksiz (E)

Division of Nephrology, Department of Internal Medicine, Dr. Lutfi Kirdar Kartal Teaching and Research Hospital, Istanbul, Turkey.

Seda Safak (S)

Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Kubra Aydin Bahat (KA)

Division of Nephrology, Department of Internal Medicine, Dr. Lutfi Kirdar Kartal Teaching and Research Hospital, Istanbul, Turkey.

Ali Riza Ucar (AR)

Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Meric Oruc (M)

Division of Nephrology, Department of Internal Medicine, Dr. Lutfi Kirdar Kartal Teaching and Research Hospital, Istanbul, Turkey.

Ozgur Akin Oto (OA)

Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Alpay Medetalibeyoglu (A)

Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Seniha Basaran (S)

Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Gunseli Orhun (G)

Department of Anesthesiology and Intensive Care, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Halil Yazici (H)

Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Aydin Turkmen (A)

Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH